SCHEMBL5895081

SCHEMBL5895081

O=C(O)/C(=C\c1ccc(-c2cccc(Cl)c2)o1)NC(=O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 6/20 0.69
LMNA P02545 2/20 0.69
MAPT P10636 12/20 0.57
ALDH1A1 P00352 6/20 0.57
MITF O75030 2/20 0.55
HTT P42858 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
GAA P10253 5/20 0.52
KDM4E B2RXH2 4/20 0.52
NPC1 O15118 1/20 0.52
HSP90AA1 P07900 1/20 0.52
RAB9A P51151 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 2/20 0.49
POLB P06746 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HCRTR1 O43613 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5895072 1.00 MAPK1 (0.69) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895090 1.00 MAPK1 (0.69) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895330 0.93 MAPK1 (0.61) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895308 0.93 MAPK1 (0.61) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895324 0.93 MAPK1 (0.61) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895805 0.89 MAPT (0.67) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895791 0.89 MAPT (0.67) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895812 0.89 MAPT (0.67) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895452 0.88 MAPK1 (0.68) MAPK1LMNAMAPTALDH1A1MITF
SCHEMBL5895442 0.88 MAPK1 (0.68) MAPK1LMNAMAPTALDH1A1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 MAPK1 1713/4885LMNA 4118/4885MAPT 3583/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI MAPK1 2559/4885LMNA 4047/4885MAPT 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.